Literature DB >> 12361699

The memory effect of heteropolyoxotungstate (PM-19) pretreatment on infection by herpes simplex virus at the penetration stage.

Katsuaki Dan1, Kiichi Miyashita, Yoshiko Seto, Haruhisa Fujita, Toshihiro Yamase.   

Abstract

The keggin-type heteropolyoxotungstate K(7)[PTi(2)W(10)O(40)].6H(2)O (PM-19) is a potent polyoxometalate (PM) inhibitor of the replication of herpes simplex virus (HSV). Pretreatment of Vero cells with PM-19 prior to HSV-2 infection enhanced the antiviral potency of PM-19 almost 10-fold compared with treatment of the cells only after infection. The pretreatment effect of PM-19 is called "the memory effect". The memory effect was reflected by inhibition of plaque formation and decrease of intracellular virus DNA quantity, and was strongest when PM-19 was present during the penetration stage of HSV-2 infection. The effect was maintained under conditions of fusion induced by polyethyleneglycol treatment. This suggests that PM-19 does not act at the fusion stage of infection. Using the infectious center assay method, it was clarified that a second round of infection was inhibited by about 30% in the presence of PM-19 at the penetration stage compared with the virus control in nontreated cells. The inhibition was enhanced to about 60% by PM-19 pretreatment prior to infection. This suggests that PM-19 pretreatment of the cells protects them against HSV-2 infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361699     DOI: 10.1016/s1043661802001706

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

1.  Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.

Authors:  Hermann Bultmann; Jeremy Teuton; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

2.  Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo.

Authors:  Wenwen Dai; Yu Wu; Jinpeng Bi; Shuai Wang; Fang Li; Wei Kong; Julien Barbier; Jean-Christophe Cintrat; Feng Gao; Daniel Gillet; Weiheng Su; Chunlai Jiang
Journal:  Viruses       Date:  2018-03-09       Impact factor: 5.048

3.  HIV-1 protease inhibition potential of functionalized polyoxometalates.

Authors:  Andreas Flütsch; Thilo Schroeder; Markus G Grütter; Greta R Patzke
Journal:  Bioorg Med Chem Lett       Date:  2010-12-25       Impact factor: 2.823

4.  Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus.

Authors:  Hong Zhang; Yanfei Qi; Yanhua Ding; Juan Wang; Qingmei Li; Jingzhou Zhang; Yanfang Jiang; Xiumei Chi; Juan Li; Junqi Niu
Journal:  Bioorg Med Chem Lett       Date:  2012-01-02       Impact factor: 2.823

5.  In vitro anti-hepatitis B and SARS virus activities of a titanium-substituted-heteropolytungstate.

Authors:  Yan-fei Qi; Hong Zhang; Juan Wang; Yanfang Jiang; Jinhua Li; Ye Yuan; Shiyao Zhang; Kun Xu; Yangguang Li; Juan Li; Junqi Niu; Enbo Wang
Journal:  Antiviral Res       Date:  2011-11-23       Impact factor: 5.970

Review 6.  Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer's disease.

Authors:  Xuechen Wang; Shengnan Wei; Chao Zhao; Xin Li; Jin Jin; Xuening Shi; Zhenyue Su; Juan Li; Juan Wang
Journal:  J Biol Inorg Chem       Date:  2022-06-17       Impact factor: 3.862

Review 7.  Polyoxometalates active against tumors, viruses, and bacteria.

Authors:  Toshihiro Yamase
Journal:  Prog Mol Subcell Biol       Date:  2013

8.  Effects of cerium and tungsten substitution on antiviral and antibacterial properties of lanthanum molybdate.

Authors:  Takumi Matsumoto; Kayano Sunada; Takeshi Nagai; Toshihiro Isobe; Sachiko Matsushita; Hitoshi Ishiguro; Akira Nakajima
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2020-08-04       Impact factor: 7.328

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.